Relief Therapeutics Holding AG (RLF) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.115x

Based on the latest financial reports, Relief Therapeutics Holding AG (RLF) has a cash flow conversion efficiency ratio of -0.115x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-3.76 Million ≈ $-4.75 Million USD) by net assets (CHF32.63 Million ≈ $41.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Relief Therapeutics Holding AG to measure how much of total assets are equity-financed.

Relief Therapeutics Holding AG - Cash Flow Conversion Efficiency Trend (2006–2024)

This chart illustrates how Relief Therapeutics Holding AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Relief Therapeutics Holding AG to evaluate the quality of earnings relative to operating cash generation.

Relief Therapeutics Holding AG Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Relief Therapeutics Holding AG ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Reino Capital SA
WAR:RNC
0.064x
Appasia Bhd
KLSE:0119
-0.022x
Daewon Media Co. Ltd
KQ:048910
-0.011x
Century Casinos Inc
NASDAQ:CNTY
0.052x
Urbanise.com Ltd
AU:UBN
-0.242x
Red Pine Exploration Inc
V:RPX
-0.383x
Cassiar Gold Corp
V:GLDC
-0.220x
First Graphene Ltd
AU:FGR
-0.095x

Annual Cash Flow Conversion Efficiency for Relief Therapeutics Holding AG (2006–2024)

The table below shows the annual cash flow conversion efficiency of Relief Therapeutics Holding AG from 2006 to 2024. For the full company profile with market capitalisation and key ratios, see Relief Therapeutics Holding AG (RLF) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CHF36.66 Million
≈ $46.35 Million
CHF-2.92 Million
≈ $-3.69 Million
-0.080x +76.41%
2023-12-31 CHF52.23 Million
≈ $66.03 Million
CHF-17.61 Million
≈ $-22.27 Million
-0.337x -103.40%
2022-12-31 CHF145.42 Million
≈ $183.85 Million
CHF-24.11 Million
≈ $-30.48 Million
-0.166x +15.73%
2021-12-31 CHF181.53 Million
≈ $229.50 Million
CHF-35.71 Million
≈ $-45.15 Million
-0.197x +27.67%
2020-12-31 CHF67.04 Million
≈ $84.76 Million
CHF-18.23 Million
≈ $-23.05 Million
-0.272x -419.88%
2019-12-31 CHF14.30 Million
≈ $18.08 Million
CHF-748.00K
≈ $-945.67K
-0.052x -80.17%
2018-12-31 CHF21.28 Million
≈ $26.91 Million
CHF-618.00K
≈ $-781.32K
-0.029x +48.15%
2017-12-31 CHF20.95 Million
≈ $26.48 Million
CHF-1.17 Million
≈ $-1.48 Million
-0.056x +56.88%
2016-12-31 CHF22.24 Million
≈ $28.11 Million
CHF-2.89 Million
≈ $-3.65 Million
-0.130x +65.57%
2015-12-31 CHF17.66 Million
≈ $22.32 Million
CHF-6.66 Million
≈ $-8.42 Million
-0.377x -13.81%
2014-12-31 CHF26.35 Million
≈ $33.31 Million
CHF-8.73 Million
≈ $-11.04 Million
-0.331x +22.01%
2013-12-31 CHF20.61 Million
≈ $26.06 Million
CHF-8.76 Million
≈ $-11.08 Million
-0.425x -124.58%
2012-12-31 CHF-2.69 Million
≈ $-3.40 Million
CHF-4.65 Million
≈ $-5.87 Million
1.729x +107.83%
2011-12-31 CHF464.04K
≈ $586.67K
CHF-10.24 Million
≈ $-12.95 Million
-22.075x -6931.42%
2010-12-31 CHF52.38 Million
≈ $66.22 Million
CHF-16.44 Million
≈ $-20.79 Million
-0.314x -437.12%
2009-12-31 CHF56.73 Million
≈ $71.73 Million
CHF-3.32 Million
≈ $-4.19 Million
-0.058x +57.83%
2008-12-31 CHF68.94 Million
≈ $87.15 Million
CHF-9.55 Million
≈ $-12.08 Million
-0.139x -139.60%
2007-12-31 CHF64.50 Million
≈ $81.54 Million
CHF-3.73 Million
≈ $-4.72 Million
-0.058x -267.47%
2006-12-31 CHF66.13 Million
≈ $83.61 Million
CHF2.28 Million
≈ $2.89 Million
0.035x --

About Relief Therapeutics Holding AG

SW:RLF Switzerland Biotechnology
Market Cap
$45.93 Million
CHF36.33 Million CHF
Market Cap Rank
#23041 Global
#204 in Switzerland
Share Price
CHF2.89
Change (1 day)
+0.87%
52-Week Range
CHF2.45 - CHF3.66
All Time High
CHF280.00
About

Relief Therapeutics Holding SA, a biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases. The company offers SETOFILM/ONDISSOLVE for nausea and vomiting associated with radiotherapy-induced, chemotherapy, and postoperative sequels; ACER-001, a sodium ph… Read more